Continuous Flow Chemistry Patents: Who Leads, Where the Gaps Are 2026
- Filings are still accelerating, with a midpoint trough in 2022 and a peak of 12 filings in 2024 — this field has not plateaued.
- China dominates the filing office count, with 15 of the tracked records filed there versus 5 each for India and WIPO PCT routes.
- No single assignee has repeat momentum, recent-year activity across tracked players sits at 1 filing or fewer, pointing to a fragmented, still-open field.
Top-5 share is the combined record count of the five largest assignees divided by all 39 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Continuous flow chemistry miniaturization covers the shift from batch reactors to microreactor and lab-on-chip platforms that run synthesis in continuous, small-volume channels rather than large stirred vessels. The patent activity tracked here sits at the intersection of process engineering and specific chemistry classes — heterocyclic compounds (C07D) and acyclic and carbocyclic compounds (C07C) are the two largest chemistry overlays on the core B01J apparatus class, meaning most filings pair a reactor design with a target synthesis route rather than claiming reactor hardware alone.
The 39 families in this dataset span 2015 through mid-2026, with filing activity concentrated more recently: the field grew from single-digit annual filings in 2017 to a 2024 peak, before the most recent year understates true activity because publication typically lags filing by around 18 months.
Filing trend and technology composition
Two views of the same 39-family dataset: filings by year, and the IPC subclasses those filings sit under.
Filing trend, 2017-2026
Annual filings moved from 8 in 2017 down through a 2022 trough of zero, then rebuilt to a peak of 12 in 2024. The 2026 figure of 1 is a partial year and should not be read as a slowdown — it reflects the publication lag inherent to any recent filing window.
IPC subclass composition
B01J covers all 39 records by definition of the search, with C07D (17) and C07C (16) the dominant chemistry overlays, C07F (organo-metallic, 4) a distant third, and A61P, B05C, C01B and H01L each appearing in only 2 records — evidence of a technology still concentrated on a narrow set of synthesis targets rather than broad application diversity.
Shares are the percentage of the 39 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Continuous Flow Chemistry Miniaturization and Integration with Eureka
This page is one run against one query. Ask Eureka your own question about continuous flow chemistry miniaturization and integration and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
Microreactor and method for continuous flow synthesis of 2,5-furandicarboxylic acid
Filed by Jiangsu University of Science and Technology, this 2025 application discloses a microreactor built from paired substrates, dual flow pumps, an injection pump, ion exchange resin and activated carbon adsorption pipes, and three T-connectors arranged to run continuous synthesis of 2,5-furandicarboxylic acid — a bio-based monomer precursor — through sequential oxidation and purification stages within the same flow path.Abstract condensed from the original filing text.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | CN107698480A | 一种无放大效应的过氧化新癸酸叔丁酯的连续流合成工艺 | 10 |
| 2 | WO2011056929A1 | Continuous flow synthesis of amino alcohols using microreactors | 9 |
| 3 | CN107698479A | 一种无放大效应的过氧化‑2‑乙基己基碳酸叔丁酯的连续流合成工艺 | 8 |
| 4 | CN107663160A | 一种4‑氯苯肼盐的连续流合成工艺 | 8 |
| 5 | US8877930B2 | Continuous flow synthesis of amino alcohols using microreactors | 8 |
| 6 | CN112457271A | 一种氨噻肟酸中间体的连续流合成方法 | 3 |
| 7 | WO2018019250A1 | 一种苯肼盐及取代苯肼盐的连续流合成工艺 | 3 |
| 8 | CN109422663A | 一种连续流合成季铵盐的方法 | 2 |
| 9 | CN107698480B | 一种无放大效应的过氧化新癸酸叔丁酯的连续流合成工艺 | 2 |
| 10 | CN113292470A | 一种无放大效应的过氧化-2-乙基己基碳酸叔丁酯的连续流合成工艺 | 2 |
Citation counts favour older records by nature of the searched corpus; treat them as a signal of historical influence within this dataset, not of current commercial importance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for R&D and IP strategy
Three patterns stand out once families, offices and citation data are read together.
Growth restarted after a flat year
The dataset shows zero filings at the 2022 midpoint followed by a rebuild to 12 filings in 2024, the highest single year on record. That shape argues against reading this as a mature, settled field — it is closer to a second wave of activity than a wind-down.
China is the largest single filing office
China accounts for 15 of the tracked records, more than triple the United States' 4. India (5) and WIPO PCT (5) filings suggest applicants are also using international routes to keep options open across multiple jurisdictions rather than committing early to one national filing.
Reactor claims are rarely filed alone
C07D (heterocyclic compounds) and C07C (acyclic/carbocyclic compounds) each appear in over 40% of records, meaning most applicants claim a specific synthesis route alongside the reactor hardware. A hardware-only claim without a target chemistry is the exception here, not the norm.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to continuous flow chemistry miniaturization and integration, with the prior art for and against each one.
Who is filing, and where the field is still open
No assignee in this dataset shows sustained recent-year momentum — the closest is a single filing with a year-over-year decline, which points to a field without an entrenched incumbent.
Actinogen Medical Ltd
The only assignee with any latest-year activity in this dataset shows a single filing, down 50% year-over-year — a signal of tapering rather than building interest from this particular filer.
MIT and named co-inventors
MIT appears in co-assignee pairs with named individual inventors, reflecting an academic filing pattern rather than a corporate portfolio build. No latest-year activity suggests this line of filing has gone quiet, at least in what has published so far.
Alfa Laval Industries and IIT Bombay
The strongest co-assignee pair in the dataset links an industrial filer with an Indian technology institute across two shared filings — one of the few signs of formal industry-academia collaboration structured into the patent record itself.
| Assignee | Recent year | YoY |
|---|---|---|
| ACTINOGEN MEDICAL LTD | 1 | -50% |
| Shanghai Huihe Huade Biotechnology Co., Ltd. | 0 | — |
| Jiangsu University of Science and Technology | 0 | — |
| Massachusetts Institute of Technology (MIT) | 0 | — |
| Alfa Laval Industries Ltd. | 0 | — |
| Indian Institute of Technology Bombay (IIT Bombay) | 0 | — |
| East China University of Science and Technology | 0 | -100% |
| US NANO LLC | 0 | — |
Where to take this analysis
The filing and citation data point to specific next steps depending on whether the goal is freedom-to-operate, portfolio building or partnership scouting.
Run a freedom-to-operate check on your synthesis target
If your route falls under C07D or C07C chemistry, check it against the highest-cited records first — those claims have already shaped how examiners read adjacent filings.
Check claim overlap in EurekaTrack the under-claimed branches before they fill in
Semiconductor-adjacent fabrication and organo-metallic flow catalysis show thin filing density today; that gap narrows as the field's overall filing rate keeps climbing.
Monitor white space in EurekaWatch for the next filing wave
The 2022 trough followed by a 2024 peak suggests filing activity moves in bursts tied to specific applicant groups rather than steady field-wide growth.
Set up alerts in EurekaCommon questions on continuous flow chemistry patents
It refers to patent claims covering synthesis reactions run in small-volume, continuous channels — microreactors or lab-on-chip devices — rather than traditional batch vessels. In this dataset, claims almost always combine a reactor apparatus (classified under B01J) with a specific target chemistry, most commonly heterocyclic or acyclic/carbocyclic compounds. That pairing matters for search strategy: a claim search on reactor hardware alone will miss most of the relevant prior art, because applicants tend to file hardware and chemistry together.
No single assignee holds a dominant, sustained filing position in this dataset. The strongest recent-year activity belongs to a single filer with just one filing and a year-over-year decline, and the strongest collaborative pair links an industrial filer with an academic institute across only two shared filings. This points to a fragmented field where influence is currently measured more by citation count on individual records than by portfolio size.
The filing trend shows a trough at the 2022 midpoint followed by a rebuild to a peak of 12 filings in 2024, which argues for acceleration rather than decline. The apparent drop-off in the most recent year is an artefact of publication lag — patent applications typically take around 18 months to publish, so the newest filing year in any dataset always understates true activity. Read the last one to two years of any flow chemistry trend with that lag in mind.
China is the largest single receiving office in this dataset with 15 records, more than three times the United States' 4. India and WIPO's PCT route each account for 5 records, and Europe (EPO) and Israel account for smaller shares. The heavy use of PCT alongside national China filings suggests some applicants are keeping international options open rather than committing to a single jurisdiction early.
The IPC composition shows thin filing density in several adjacent branches: organo-metallic flow catalysis (C07F, 4 records), semiconductor-adjacent microfluidic fabrication (H01L, 2 records), and therapeutic-compound flow synthesis (A61P, 2 records) all sit well below the dominant C07D and C07C chemistry classes. A first claim in one of these branches — for example, a microreactor architecture specifically adapted for organo-metallic catalyst stability — would face far less crowded prior art than a general heterocyclic synthesis claim.
Research Continuous Flow Chemistry Miniaturization and Integration in depth with Eureka
Go past this page: query the whole continuous flow chemistry miniaturization and integration corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.